News in other languages: NEOVACS

08-07	Bourse : Eutelsat souffre, la tech américaine s'offre un baroud d'honneur nocturne
08-07	Néovacs accepte un accord stratégique à plus de 25 millions de dollars
08-07	Neovacs : Néovacs a accepté une lettre d’intention engageante portant sur l’acquisition d’une partie de sa propriété intellectuelle et un accompagnement dans leur valorisation pour un montant total pouvant dépasser 25 MEUR
08-07	L'énigmatique Mister Warsh, le marché du travail et les taux
06-30	Neovacs renforce son portefeuille stratégique de propriété intellectuelle

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-1.60%	+0.86%	+3.70%	+14.57%	49.54B
REVOLUTION MEDICINES, INC.	-0.34%	+3.80%	+480.80%	+582.63%	44.06B
BEONE MEDICINES AG	-0.29%	+9.26%	+24.21%	+75.30%	40.85B
IQVIA HOLDINGS INC.	-0.55%	+2.91%	+30.66%	+10.35%	40.14B
CELLTRION, INC.	-4.04%	+8.72%	+22.60%	+48.00%	34.17B
MEDPACE HOLDINGS, INC.	-1.06%	+1.85%	+30.33%	+125.36%	16.9B
ASCENDIS PHARMA A/S	+0.64%	+4.77%	-	-	16.78B
EUROFINS SCIENTIFIC SE	-0.43%	-0.11%	+4.22%	+20.71%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.82%	+10.11%	+87.93%	+32.35%	13.46B
Average	-0.62%	+6.97%	+85.56%	+113.66%	29.99B
Weighted average by Cap.	-0.92%	+6.51%	+103.17%	+135.77%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

06-30	Neovacs bolsters its strategic intellectual property portfolio
02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI

Market Cap	4.09K 4.72K 3.83K 3.49K 6.57K 450K 6.67K 45.06K 17.61K 225K 17.72K 17.33K 752K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -232K -188K -172K -323K -22.13M -328K -2.21M -866K -11.08M -871K -852K -36.94M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99%	Yield 2023 *	-	Yield 2024	-

06-30	Neovacs bolsters its strategic intellectual property portfolio
02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates

	2023	2024
Net sales	533K 616K 500K 456K 857K 58.72M 870K 5.88M 2.3M 29.4M 2.31M 2.26M 98.04M	434K 501K 407K 371K 697K 47.77M 708K 4.78M 1.87M 23.92M 1.88M 1.84M 79.76M
Net income	-8.74M -10.09M -8.19M -7.47M -14.05M -963M -14.26M -96.35M -37.66M -482M -37.89M -37.07M -1.61B	-32.91M -37.99M -30.84M -28.13M -52.88M -3.62B -53.69M -363M -142M -1.81B -143M -140M -6.05B
Net Debt	-237K -273K -222K -202K -380K -26.04M -386K -2.61M -1.02M -13.04M -1.02M -1M -43.47M	-205K -237K -192K -175K -329K -22.58M -335K -2.26M -883K -11.3M -889K -869K -37.69M

NEOVACS Stock Xetra

Stocks

0LW

FR0004032746

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile

End-of-day quote Xetra
- ^EUR	-